Board of Visitors leadership welcomes new members
The University of Texas MD Anderson Cancer Center Board of Visitors (BOV), a nonfiduciary, appointed advisory board of volunteers who advance the institution’s mission to end cancer, marks the beginning of Fiscal Year 2019 with nine new members, effective Sept. 1:
Combination immunotherapy shrinks melanoma brain metastases
Combination immunotherapy shrank melanoma that has spread to the brain in more than half of the patients in a clinical trial reported in the...
PARP inhibitor improves progression-free survival in patients with advanced breast cancers and BRCA mutations
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended...
MD Anderson ranked No. 1 for cancer care in national survey
The University of Texas MD Anderson Cancer Center again has been ranked No. 1 for cancer care by U.S. News & World Report’s annual “Best Hospitals” survey. Since the survey began in 1990, MD Anderson has been named one of the top two cancer hospitals, and it has ranked first 14 times in the last 17 years.
“MD Anderson is proud and grateful to be recognized once again as the leading cancer center in the nation, an honor that...
MD Anderson and Jazz Pharmaceuticals collaborate to evaluate potential treatment options for hematologic malignancies
The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year collaboration agreement with a...
Comprehensive CAR T-cell therapy pediatric guidelines developed by MD Anderson in collaboration with the Pediatric Acute Lung Injury and Sepsis Investigators network
Almost one year after the U.S. Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children...